Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial

BackgroundChronic kidney disease-associated pruritus (CKD-aP) is a common and distressing symptom in hemodialysis patients. This Phase II trial evaluated the efficacy and safety of HSK21542, a selective kappa-opioid receptor agonist, in managing CKD-aP.MethodsAdult patients on hemodialysis with mode...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ming-Ming Pan, Min Gao, Li Zhou, Yan Xu, Li Yao, Chao-Qing Wu, Chang-Lin Mei, Zhan-Zheng Zhao, Dong Sun, Tian-Jun Guan, Qin-Kai Chen, Ming Shi, Hui Xu, Ya-Ming Li, Wan-Yun Zhao, Rui Yan, Bi-Cheng Liu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2025-06-01
coleção:	Frontiers in Pharmacology
Assuntos:	CKD-aP HSK21542 hemodialysis κ-opioid receptor agonist uremic pruritus
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1583515/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!